Opinion
Video
Author(s):
The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Revisit the OncLive On Air Episodes From February 2024
Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL
WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC